A

Agilent Technologies Inc
NYSEHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$42.54B
P/E Ratio
29.76
EPS
$5.07
Beta
1.24
52W High
$163.75
52W Low
$108.14
50-Day MA
$142.33
200-Day MA
$131.59
Dividend Yield
0.68%
Profit Margin
19.50%
Forward P/E
21.69
PEG Ratio
1.24

About Agilent Technologies Inc

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Official WebsiteUSAFY End: October

Fundamentals

Revenue (TTM)$7.37B
Gross Profit (TTM)$3.96B
EBITDA$2.08B
Operating Margin25.60%
Return on Equity21.00%
Return on Assets8.63%
Revenue/Share (TTM)$26.10
Book Value$26.11
Price-to-Book5.74
Price-to-Sales (TTM)5.77
EV/Revenue6.03
EV/EBITDA21.85
Quarterly Earnings Growth (YoY)8.50%
Quarterly Revenue Growth (YoY)8.10%
Shares Outstanding$281.97M
Float$280.96M
% Insiders0.20%
% Institutions95.58%

Historical Volatility

HV 10-Day
27.78%
HV 20-Day
28.05%
HV 30-Day
25.73%
HV 60-Day
28.13%
HV Rank
27.4%

Volatility is currently expanding

Analyst Ratings

Consensus ($175.45 target)
4
Strong Buy
12
Buy
6
Hold

Latest News

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent's ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.

Business Wire9/4/2026Neutral
Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance

Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operating margin jump nearly 600 bps to 23.5%. Guidance for Q4 and FY26 implies continued momentum, with management projecting 6.5–7.5% revenue growth and 8.5% EPS growth for Q4.

Seeking Alpha8/27/2026Positive
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core(1) compared with the third quarter of fiscal year 2025. Third-quarter GAAP net income was $362 million, or $1.28 per share. This compares with $336 million, or $1.18 per share, in the third quarter of fiscal year 2025. Non-GAAP net income(3) was $459 million (including a $17 million net.

Business Wire8/26/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on A and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026